Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer

Yu Kyung Cho, Myung-Gyu Choi, Suck Chei Choi, Kee Myung Lee, Tae Oh Kim, Soo-Heon Park, Jeong Seop Moon, Yun Jeong Lim, Dae Hwan Kang, Gab Jin Cheon, Gwang Ho Baik, Kyoung Oh Kim, Kwang Bum Cho, Jin Seok Jang, Jong-Jae Park, Byoung Kwan Son, Hye-Kyung Jung, Byung-Wook Kim, Sung Kuk Kim, Soo Teik Lee, Jae Myung Cha, Ah Rong Kim, Eun Ji Kim, Hyun Wook Park, Geun Seog Song, Yu Kyung Cho, Myung-Gyu Choi, Suck Chei Choi, Kee Myung Lee, Tae Oh Kim, Soo-Heon Park, Jeong Seop Moon, Yun Jeong Lim, Dae Hwan Kang, Gab Jin Cheon, Gwang Ho Baik, Kyoung Oh Kim, Kwang Bum Cho, Jin Seok Jang, Jong-Jae Park, Byoung Kwan Son, Hye-Kyung Jung, Byung-Wook Kim, Sung Kuk Kim, Soo Teik Lee, Jae Myung Cha, Ah Rong Kim, Eun Ji Kim, Hyun Wook Park, Geun Seog Song

Abstract

Background: Tegoprazan is a novel potassium-competitive acid blocker for the treatment of acid-related disorders.

Aims: To assess whether tegoprazan is non-inferior to lansoprazole in terms of efficacy and safety in patients with gastric ulcers.

Methods: In this phase 3, double-blind, active control, multicentre study, 306 gastric ulcer patients were randomised to one of three treatment groups: tegoprazan 50 mg, tegoprazan 100 mg and lansoprazole 30 mg once daily for 4 or 8 weeks. The primary endpoint was the cumulative proportion of patients with healed ulcers confirmed by endoscopy up to 8 weeks from treatment initiation. Symptoms and safety were assessed.

Results: In the full analysis set, the cumulative healing rates at week 8 were 94.8% (91/96) for the tegoprazan 50 mg, 95.0% (94/99) for the tegoprazan 100 mg and 95.7% (89/93) for the lansoprazole 30 mg groups. At week 4, the respective healing rates were 90.6% (87/96), 91.9% (91/99), and 89.2% (83/93). In per protocol analysis, 4-week healing rates were 95.4% (84/88), 94.6% (88/93) and 92.9% (79/85) for tegoprazan 50 mg, tegoprazan 100 mg and lansoprazole 30 mg, respectively. Both doses of tegoprazan were non-inferior to lansoprazole in ulcer healing at 4 and 8 weeks. The incidence of drug-related treatment-emergent adverse events did not differ among groups. The increase in serum gastrin concentration was not higher in tegoprazan-treated patients than in lansoprazole-treated patients.

Conclusions: Tegoprazan 50 or 100 mg were not inferior to lansoprazole 30 mg once daily in the treatment of gastric ulcers.

© 2020 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.

Figures

FIGURE 1
FIGURE 1
Disposition of Subjects
FIGURE 2
FIGURE 2
Gastrin levels from baseline (pg/mL) during treatment and follow‐up periods (safety set)

References

    1. Hunt RH, Cederberg C, Dent J, et al. Optimizing acid suppression for treatment of acid‐related diseases. Dig Dis Sci. 1995;40:24S‐49S.
    1. Huang JQ, Hunt RH. Pharmacological and pharmacodynamic essentials of H2‐receptor antagonists and proton pump inhibitors for the practising physician. Best Pract Res Clin Gastroenterol. 2001;15:355‐370.
    1. Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013;19:25‐35.
    1. Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: a comprehensive review. Gut Liv. 2017;15:27‐37.
    1. Oshima T, Miwa H. Potent potassium‐competitive acid blockers: a new era for the treatment of acid‐related diseases. J Neurogastroenterol Motil. 2018;30:334‐344.
    1. Mori H, Suzuki H. Role of acid suppression in acid‐related diseases: proton pump inhibitor and potassium‐competitive acid blocker. J Neurogastroenterol Motil. 2019;25:6‐14.
    1. Matsukawa J, Hori Y, Nishida H, et al. A comparative study on the modes of action of TAK‐438, a novel potassium‐competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol. 2011;81:1145‐1151.
    1. Echizen H. The first‐in‐class potassium‐competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2016;55:409‐418.
    1. Jung YS, Kim EH, Park CH. Systematic review with meta‐analysis: the efficacy of vonoprazan‐based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther. 2017;46:106‐114.
    1. Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016;43:240‐251.
    1. Komori H, Ueyama H, Nagahara A, et al. A prospective randomized trial of a potassium competitive acid blocker vs proton pump inhibitors on the effect of ulcer healing after endoscopic submucosal dissection of gastric neoplasia. J Int Med Res. 2019;47:1441‐1452.
    1. Miwa H, Uedo N, Watari J, et al. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers ‐ results from two phase 3, non‐inferiority randomised controlled trials. Aliment Pharmacol Ther. 2017;45:240‐252.
    1. Liu C, Feng BC, Zhang Y, Li LX, Zuo XL, Li YQ. The efficacy of vonoprazan for management of post‐endoscopic submucosal dissection ulcers compared with proton pump inhibitors: a meta‐analysis. J Dig Dis. 2019;20:503‐511.
    1. Takahashi N, Take Y. Tegoprazan, a novel potassium‐competitive acid blocker to control gastric acid secretion and motility. J Pharmacol Exp Ther. 2018;364:275‐286.
    1. Han S, Choi HY, Kim YH, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ‐12420), a novel potassium‐competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2019;50:751‐759.
    1. Scarpignato C, Hunt RH. Editorial: potassium‐competitive acid blockers for acid‐related diseases—tegoprazan, a new kid on the block. Aliment Pharmacol Ther. 2019;50:960‐962.
    1. Kim DK, Lee KH, Kim SJ, et al. Effects of tegoprazan, a novel potassium‐competitive acid blocker, on rat models of gastric acid‐related disease. Pharmacol Exp Ther. 2019;369:318‐327.
    1. Lee KJ, Son BK, Kim GH, et al. Randomised phase 3 trial: tegoprazan, a novel potassium‐competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis. Aliment Pharmacol Ther. 2019;49:864‐872.
    1. Gerson LB, Fass R. A systematic review of the definitions, prevalence, and response to treatment of nocturnal gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2009;7:372‐378.
    1. Orr WC. Review article: sleep‐related gastro‐oesophageal reflux as a distinct clinical entity. Aliment Pharmacol Ther. 2010;31:47‐56.
    1. Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology. 2008;134:1842‐1860.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera